The EU Commission reviews the merger between two biotech company specialised in genomic sequencing (Illumina / Grail)

The European Commission opens a review of Illumina's acquisition of Grail under the procedure of Article 22 of the 2004 Merger Regulation* Background Following the referral request submitted by the Autorité de la concurrence, which was joined by several Member States of the European Economic Area (Belgium, Greece, Iceland, the Netherlands, Norway), the Commission has decided to open an examination on Illumina's acquisition of Grail’s transaction (see press release of 20 April 2021). This is the first time since Margrethe Vestager’s announcement of her new approach in terms of merger control of "below the threshold" transactions under Article 22 of Regulation 139/2004, that the Commission will examine a merger transaction that was not submitted to a mandatory notification in terms of

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

French Competition Authority, The EU Commission reviews the merger between two biotech company specialised in genomic sequencing (Illumina / Grail), 20 avril 2021, e-Competitions April 2021, Art. N° 100379

Visites 184

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues